RVMD
Revolution Medicines Inc
NASDAQ: RVMD · HEALTHCARE · BIOTECHNOLOGY
$153.87
+3.11% today
Updated 2026-06-12
Market cap
$32.71B
P/E ratio
—
P/S ratio
9,035.10x
EPS (TTM)
$-7.11
Dividend yield
—
52W range
$34 – $167
Volume
3.3M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-1.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$120.47
-21.71%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy17 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.10x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -0.99 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-355.70M
- Revenue declining -95.20% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $35.38M | $11.58M | $0.00 | $0.00 | $742000.00 | $0.1B |
| Net income | $-248.71M | $-436.37M | $-600.09M | $-1.13B | $-453.82M | — |
| EPS | — | — | — | — | $-7.11 | $-7.47 |
| Free cash flow | $-235.22M | $-358.30M | $-567.74M | $-913.73M | $-355.70M | — |
| Profit margin | -702.95% | -3,768.28% | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-26 | MANCINI, ANTHONY | Sale | 3,121 | — |
| 2026-05-26 | MANCINI, ANTHONY | Buy | 3,121 | $33.62 |
| 2026-05-26 | MANCINI, ANTHONY | Sale | 2,000 | $154.06 |
Peer comparison
Smart narrative
Revolution Medicines Inc trades at $153.87. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -0.99, it sits in the distress. TTM revenue stands at $742000.00.
Frequently asked questions
What is Revolution Medicines Inc's stock price?
Revolution Medicines Inc (RVMD) trades at $153.87, on a P/S of 9,035.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Revolution Medicines Inc overvalued?
Revolution Medicines Inc carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Revolution Medicines Inc (RVMD)?
The 12-month analyst consensus target is $120.47, about 21.7% below the current $153.87. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of RVMD by 2030?
Our research-backed model puts the 2030 base case at $152.58, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Revolution Medicines Inc's revenue?
Revolution Medicines Inc's trailing twelve-month revenue is $742000.00, and our model projects it reaching about $2.65B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Revolution Medicines Inc's Altman Z-Score is -0.99, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9,035.10x
ROE-91.45%
Beta1.41
50D MA$141.50
200D MA$92.76
Shares out0.21B
Float0.19B
Short ratio—
Avg volume3.3M
Performance
1 week+0.00%
1 month+6.89%
3 months+64.13%
YTD+95.47%
1 year—
3 years—
5 years—